ClinicalTrials.Veeva

Menu

Platelet Sub-study of the Neomindset Trial

H

Hospital Israelita Albert Einstein

Status and phase

Active, not recruiting
Phase 4

Conditions

Acute Coronary Syndrome

Treatments

Drug: Dual antiplatelet therapy: Acetylsalicylic acid + ticagrelor OR Acetylsalicylic acid + prasugrel
Drug: Monotherapy: Ticagrelor alone OR Prasugrel alone

Study type

Interventional

Funder types

Other

Identifiers

NCT05767723
Platelet

Details and patient eligibility

About

The general purpose of the Neomindset trial is to evaluate the non-inferiority hypothesis for ischemic events and the superiority hypothesis for bleeding events resulting from platelet P2Y12 receptor inhibitors given as monotherapy in comparison with conventional dual antiplatelet therapy in acute coronary syndrome patients treated with percutaneous coronary intervention.

The platelet sub-study will be conducted at the Hospital Israelita Albert Einstein. This sub-study will recruit randomized patients from the Neomindset trial to evaluate platelet function after at least 30 days of study treatment with either P2Y12 inhibitor monotherapy or dual antiplatelet therapy.

Full description

The platelet sub-study will be conducted at the Hospital Israelita Albert Einstein. This sub-study will recruit randomized patients from the Neomindset trial to evaluate platelet function after at least 30 days of study treatment with either P2Y12 inhibitor monotherapy or dual antiplatelet therapy.

These patients will undergo blood sampling and measurement of platelet function after being treated with P2Y12 inhibitor monotherapy or dual antiplatelet therapy for at least 30 days.

Enrollment

48 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Age >=18 years;
  • Clinical presentation compatible with acute coronary syndrome with onset < 24 hours before admission;
  • Successful percutaneous coronary intervention(s) of all target lesions (culprit and non-culprit) with new-generation drug-eluting stents;
  • Length of stay in hospital at randomization < 96 hours;
  • Subjects will be informed about the nature of the study and must agree to comply and give an informed consent in writing using a form approved in advance by the local Ethics Committee.

Exclusion criteria

  • Acute coronary syndrome on index admission treated in a conservative way or by unsuccessful percutaneous intervention or surgically;
  • Presence of residual lesions which are likely to require future treatment in the next 12 months;
  • Fibrinolytic therapy < 24 hour before randomization;
  • Need of oral anticoagulation with warfarin or new anticoagulants;
  • Chronic bleeding diathesis;
  • Active or recent major bleeding (in-hospital);
  • Prior intracranial hemorrhage;
  • Ischemic cerebrovascular accident < 30 days;
  • Presence of brain arteriovenous malformation;
  • Index event of non-atherothrombotic etiology (i.e., stent thrombosis, coronary embolism, spontaneous coronary artery dissection, myocardial ischemia due to supply/demand imbalance);
  • Potential or scheduled cardiac or non-cardiac surgery in the next 12 months;
  • Platelet count < 100,000 cells/mm3 or > 700,000 cells/mm3;
  • Total white blood count < 3,000 cells/mm3;
  • Suspected or documented active liver disease (including laboratory evidence of hepatitis B or C);
  • Receiver of heart transplant;
  • Known allergies or intolerance of acetylsalicylic acid, clopidogrel, ticlopidine, ticagrelor, prasugrel, heparin or antiproliferative agents from the limus-family of drugs;
  • Subject with life expectation lower than 1 year;
  • Any significant medical condition that, in the investigator's opinion, could interfere with the ideal participation of the subject in the study;
  • Participation in other study in the past 12 months, unless a direct benefit to the subject can be expected.
  • Impossibility of being treated with dual antiplatelet therapy for 12 months, based on investigator judgement.

Trial design

Primary purpose

Diagnostic

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Single Blind

48 participants in 2 patient groups

Acetylsalicylic acid + ticagrelor OR Acetylsalicylic acid + prasugrel
Active Comparator group
Description:
Subjects randomized to Dual Antiplatelet Therapy Control Group will be treated with a regimen of acetylsalicylic acid combined with ticagrelor or prasugrel for 12 months. Acetylsalicylic acid (100 mg/day) + ticagrelor (90 mg twice daily) Or Acetylsalicylic acid (100 mg/day) + prasugrel (10 mg once daily)
Treatment:
Drug: Dual antiplatelet therapy: Acetylsalicylic acid + ticagrelor OR Acetylsalicylic acid + prasugrel
Ticagrelor alone or prasugrel alone
Experimental group
Description:
All subjects randomized to Monotherapy Group will have acetylsalicylic acid discontinued immediately after randomization. Subjects randomized to Monotherapy Group will be treated with ticagrelor (90 mg twice daily) or prasugrel alone (10 mg once daily) for 12 months. Ticagrelor alone (90 mg twice daily) Or Prasugrel alone (10 mg once daily)
Treatment:
Drug: Monotherapy: Ticagrelor alone OR Prasugrel alone

Trial contacts and locations

1

Loading...

Central trial contact

Thiago P Oliveira, MD; Pedro A Lemos, MD, PhD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems